NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

ClearPoint Neuro, Inc. (CLPT) Stock Analysis

ClearPoint Neuro, Inc. (CLPT) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

CLPT

$13.96

−$0.09 (−0.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLPT with… →

CLPT Key Statistics

As of Sep 4, 2026
Trading
Open
$14.00
Previous Close
$14.05
Day's Range
13.78–14.09
52-Week Range
8.27–30.10
Volume
384.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$425.84M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.61
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.17
Financials (FY)
Revenue (FY)
$36.97M+17.78%
Net Income (FY)
−$25.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−81.76%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.50M
1-Year Return
+25.99%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
723.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLPT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.05%
2025−11.05%
2024+126.51%
2023−19.83%
2022−24.51%
2021−29.39%
2020+231.04%
2019+205.73%
2018−42.91%
2017−19.12%
2016 (partial year)−47.69%

As of September 4, 2026.

CLPT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$36.97M−$25.54M−69.1%
2024$31.39M−$18.91M−60.3%
2023$23.96M−$22.09M−92.2%
2022$20.55M−$16.44M−80.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$36.97M$22.69M−$24.16M−$25.54M−69.1%
2024$31.39M$19.12M−$19.73M−$18.91M−60.3%
2023$23.96M$13.61M−$22.45M−$22.09M−92.2%
2022$20.55M$13.53M−$16.33M−$16.44M−80.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLPT Valuation vs Medical Devices Median

Median of 151 stocks
MetricCLPTMedical Devices medianvs median
P/S ratio10.072.983.4x the median
Profit margin−81.76%−1.69%80.1 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ClearPoint Neuro, Inc. (CLPT) is capitalised at $425.84M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 160.

The 52-week range on file runs from $8.27 to $30.10. The most recent close on file for CLPT is $13.96, dated September 4, 2026. That is −$0.09 (−0.64%) against the previous close. The latest close sits 68.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $36.97M. That is +17.78% against the prior fiscal year, when revenue was $31.39M. The same year closed with a net loss of $25.54M. The reported profit margin is −81.76%. That is 80.1 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −1.17.

Across the 4 fiscal years on file, revenue moves from $20.55M in 2022 to $36.97M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.61. Measured against sales, the shares trade at 10.07 times revenue. On price-to-sales that is 3.4 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned +25.99%. Across 10 years the annualized return works out at +9.14%. Beta against the wider market is reported at 1.27. Daily returns over the trailing 10 years annualize to a volatility of 84.38%.

Growth & Income

The record shows no dividend for CLPT.

So far in 2026 the price is +2.05%. The strongest complete calendar year on file is 2020 at +231.04%; the weakest is 2018 at −42.91%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

ClearPoint Neuro, Inc. (CLPT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ClearPoint Neuro, Inc. CLPT $425.84M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. ClearPoint Neuro, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Visit website →